27-28 September, 2018

Boston, USA

Speakers

Expand/Collapse

Mahmoud Ameri
VP- Research & Development
Zosano Pharma

Dr. Ameri is one of the co-founders of Zosano Pharma, and brings 20 years of drug delivery, preclinical and early ex U.S. clinical development of combination products to the company. He is responsible for research and development. Prior to Zosano, he was at Alza/J&J were he co-invented and developed the Adhesive Dermally Applied Microarray system and holds over 20 patents and patent applications all relating to the Zosano drug delivery technology. Dr. Ameri received his PhD from the School of Pharmacy at the University of Manchester in the United Kingdom

Day Two

Friday, 28 September, 2018

12.00 | Adhesive Dermally Applied Microarray (ADAM) for the Treatment of Acute Migraine.

Scott Dax
CSO
CerSci Therapeutics

Dr. Scott L. Dax has over 25 years of experience guiding research & development at both large pharma houses and small biotechnology companies. His leadership roles span chemistry, drug discovery, pharmacology and technology. Currently Scott is Chief Scientific Officer at CerSci Therapeutics (www.cersci.com). The mission of CerSci Therapeutics is singular- pain relief from new drugs developed from understanding mechanisms which cause pain, and conquering resultant neuronal sensitization. CerSci is poised to deliver a new generation of non-opioids to treat acute post-surgical pain and chronic painful diabetic neuropathy. Scott is also a Project Director at BioMotiv, a mission-driven development company associated with The Harrington Project for Discovery & Development, a national initiative centered at University Hospitals Cleveland Medical Center. The company’s focus is accelerating breakthrough discoveries from research institutions into therapeutics for patients.

Day One

Thursday, 27 September, 2018

16.00 | Case Study:CT-044: A Reactive Species Decomposition Accelerant (RSDAx) for the Treatment of Acute Incisional Pain and Chronic Diabetic Neuropathy

Marzia Martina
Team Leader
National Research Council of Canada

Dr Marzia Martina is the leader of the Electrophysiology Team within the Department of Translational Biosciences at the National Research Council of Canada. Her work focuses on the development of therapeutic antibodies targeting ion channels, as well as physiologically-relevant CNS models to evaluate therapeutics. Prior to joining the NRC, she was Assistant Professor at the Department of Psychiatry (University of Ottawa) conducting electrophysiological studies on the effects of D-amino acids on NMDA receptor function. During her postdoctoral fellowship, she studied the physiological and networking properties of central and intercalated neurons in the amygdala at Laval University, Quebec City. Dr Martina holds a PhD in Human Physiology from the University of Milan where she investigated the modulatory effects of dopamine on HVA calcium channels in sensory neurons.  

Day One

Thursday, 27 September, 2018

14.00 | Case Study:Development of functional antibodies against human Nav1.7 to modulate pain

Joseph Stauffer
CMO
Cara Therapeutics

Day One

Thursday, 27 September, 2018

11.30 | Case Study:Developing a first-in-class Peripheral Kappa Opioid Receptor Agonist for Pain and PONV

Mary Ann Pellymounter
Program Director
NIH/NINDS/ Division of Translational Research

Day Two

Friday, 28 September, 2018

09.30 | Case Study:Promotion of Best Practices in Biomarker Discovery and Validation: A New Program at NINDS with an Emphasis on Pain Biomarkers

Kerrie Brady
CBO & Exec VP Strategy
Centrexion Corp.

James Ellis
CSO
Carica Health

Day One

Thursday, 27 September, 2018

15.00 | Case Study:Selective Targeting of Sodium Channel Blockers into Nociceptors to Produce Analgesia

Lucio Rovati
CEO & CSO
Rottapharm Biotech

Day One

Thursday, 27 September, 2018

10.00 | Case Study:Targeting Imidazoline-2 Receptors In the Development of New Non-Opioid Analgesics and as a Safe, Non-Addictive Combination with Low-Dose Opioids

Alexandros Makriyannis
Chemistry & Chemical Biology Director
The Center for Drug Discovery Northeastern University

Post-Conference Workshop

Friday, 28 September, 2018

15.00 | Translation from Animal to Human: A Workshop on Strategies & Applications

Day One

Thursday, 27 September, 2018

12.00 | Case Study:The Cannabinoid System as a Therapeutic Target for Pain

Craig Hartrick
President of World Institute of Pain; President & CSO
Caventure Drug Discovery, Inc.

Day One

Thursday, 27 September, 2018

16.30 | Panel Discussion:Challenges in Design and Interpretation of Pain Clinical Trials and How to Overcome Them?

10.30 | Case Study:Beyond Mu: Novel Opioid Development

09.00 | Case Study:Opioid Crisis at a Glance from the R&D Perspective

Andrew Alt
Director, Center for Chemical Genomics
University of Michigan

Day One

Thursday, 27 September, 2018

09.30 | Case Study:Allosteric Modulators of Opioid Receptors: A Novel Approach to Safer Pain Therapeutics

Daniel Klamer
VP, Business Development & Scientific Strategy
Anavex Life Sciences Corp.

Day One

Thursday, 27 September, 2018

14.30 | Case Study:ANAVEX®1066, a Sigma-1 Receptor Antagonist, as a Therapeutic Candidate for Pain

Silviu Itescu
CEO & Executive Director
Mesoblast Ltd.

Day One

Thursday, 27 September, 2018

16.30 | Panel Discussion:Challenges in Design and Interpretation of Pain Clinical Trials and How to Overcome Them?

Day Two

Friday, 28 September, 2018

11.00 | Case Study:Mesenchymal Precursor Cells as a Non-Opioid Treatment for Low Back Pain

Daniela Salvemini
Professor of Pharmacological and Physiological Science
Saint Louis University

Day One

Thursday, 27 September, 2018

12.30 | Case Study:Highly Selective A3AR Agonists as Novel Non-Narcotic Analgesics

Jeffrey Mogil
E.P. Taylor Professor of Pain Studies
McGill University

Day Two

Friday, 28 September, 2018

09.00 | Case Study:Pain in Mice and Man: Ironic Adventures in Translation

Srinivasan Venkatachalan
Assistant Principal Scientist
Therapeutic Chromocell

Dr. Venkatachalan received his MS and PhD in 2008 in physiology with a concentration in neuroscience from the University of Wisconsin at Madison after his BS in Pharmaceutical Sciences from the Delhi Institute of Pharmaceutical Sciences and Research in India.  His thesis focused on elucidating structure-function relationships in the GABA(A) receptor underlying agonist activation and allosteric modulation by benzodiazepines and barbiturates.  Sri has worked on both ion channel and GPCR molecular targets for indications ranging from CF, sperm motility to taste modulation at Chromocell.  Currently, Sri is an Assistant Principal Scientist and works within the pain therapeutic group whose mission is to identify novel, selective and potent modulators of voltage gated sodium channels.  In addition, Sri also oversees administrative functioning of Chromocell’s cell culture, assay development, night time crew and robotics core biology groups

Day Two

Friday, 28 September, 2018

11.30 | Case Study:CC8464, Novel, Peripherally Restricted Pain Inhibitor Targeting Nav1.7

Andrea Hohmann
Linda and Jack Gill Chair of Neuroscience and Professor of Psychological and Brain Sciences
Indiana University

Day Two

Friday, 28 September, 2018

12.30 | Case Study:Targeting Cannabinoid CB2 Receptors to Suppress Opioid Tolerance and Physical Dependence